Search hospitals > Washington > Spokane
MultiCare Deaconess Cancer and Blood Specialty Center - Valley
Claim this profileSpokane, Washington 99216
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
77 reported clinical trials
2 medical researchers
Summary
MultiCare Deaconess Cancer and Blood Specialty Center - Valley is a medical facility located in Spokane, Washington. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. MultiCare Deaconess Cancer and Blood Specialty Center - Valley is involved with conducting 77 clinical trials across 249 conditions. There are 2 research doctors associated with this hospital, such as Alison K. Conlin and Jennifer Slim.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Alison K. ConlinProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
103 reported clinical trials
179 drugs studied
Jennifer SlimMultiCare Tacoma General Hospital6 years of reported clinical research
Studies Cancer
Studies Breast Cancer
18 reported clinical trials
50 drugs studied
Clinical Trials running at MultiCare Deaconess Cancer and Blood Specialty Center - Valley
Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Bladder Cancer
Ovarian Tumors
Pancreatic Carcinoma
Cancer
Testicular Carcinoma
Ovarian Carcinoma
Ovarian Choriocarcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at MultiCare Deaconess Cancer and Blood Specialty Center - Valley?
MultiCare Deaconess Cancer and Blood Specialty Center - Valley is a medical facility located in Spokane, Washington. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. MultiCare Deaconess Cancer and Blood Specialty Center - Valley is involved with conducting 77 clinical trials across 249 conditions. There are 2 research doctors associated with this hospital, such as Alison K. Conlin and Jennifer Slim.